Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Campbell Soup Earnings Are Good Food for Investors

Now serving much more than just soup, shares of multi-brand food conglomerate Campbell Soup Co. are trading 10% higher today as the firm announced better than expected annual earnings. Shares of Campbell Soup Company (CPB:NYSE) are trading more than 10% higher today...
Streetwise Reports | September 3, 2019 |

Lifeway Foods' Shares Rise 40% on Positive Q1 Sales Data with March Revenue Up 13% Y-O-Y

Shares of Lifeway Foods traded higher as the company reported it has increased production to support accelerated demand during the COVID-19 health crisis. Lifeway Foods Inc. (LWAY:NASDAQ) yesterday provided a business update together with reporting its Q4...
Streetwise Reports | April 16, 2020 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...
Streetwise Reports | July 2, 2020 |

Introducing: The Device to Replace Antiquated Paper-Based Systems

(Image via Visionstate Corp. Click to enlarge.) The Internet of Things (IoT) describes the network of physical objects “things” that are embedded with sensors, software, and other technologies for the purpose of connecting and exchanging data ...
Featured Submission | March 1, 2022 |

17 best payday loans online: Quick cash and fast approval this Christmas

If you face a financial emergency, traditional loans may not be a viable option if you have bad credit. So what can you do when you need quick cash – especially close if you need cash for Christmas gifts during the festive season? The best online payday loans are an a...
Dominic Castleberry | December 11, 2023 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |

'Topline Beat, All Eyes on Potential M&A' by Health Technologies Firm

An update on the Canadian company, including its Q2/19 results and its next expected catalyst, is provided in a Haywood report. In an Aug. 23 research note, analyst Daniel Rosenberg reported that his firm Haywood increased its price target on WELL Health Technologies...
Streetwise Reports | August 28, 2019 |
1 2 3 4 5 6 7 8 9 10 ...